<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Molecular <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> are precursors of postoperative recurrence, detected by molecular-biological tools </plain></SENT>
<SENT sid="1" pm="."><plain>Chemokines and their receptors contribute to dissemination and local immune recognition </plain></SENT>
<SENT sid="2" pm="."><plain>A strong expression of the chemokine receptor CCR5 is associated with non-<z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> and increased CD8+ T-cell infiltration </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to analyze whether CCR5 expression correlates with the presence of hepatic molecular <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (MM) </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Ninety-three patients undergoing elective surgery for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>The K-ras mutation status was defined by PCR-RFLP, and the CCR5 expression status was analyzed by CCR5-specific reverse transcription (RT-PCR) analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Liver biopsy samples had been intra-operatively taken to screen for MM </plain></SENT>
<SENT sid="7" pm="."><plain>MM were detected by K-ras-specific PCR-RFLP and nested CK20/GCC RT-PCR </plain></SENT>
<SENT sid="8" pm="."><plain>Prevalence of MM was correlated with CCR5 expression status </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> harboured K-ras mutations in 53% (codon 12: 47%; codon 13: 6%) of cases </plain></SENT>
<SENT sid="10" pm="."><plain>Among K-ras mutants, MM were detected in 27-53% of patients, dependent on the technique applied (K-ras-specific PCR-RFLP assay vs. nested CK20/GCC RT-PCR approach (P = 0.004)) </plain></SENT>
<SENT sid="11" pm="."><plain>CCR5 expression of K-ras mutants ranged from absent (23/49: 47%), weak (17/49: 35%), intermediate (4/49: 8%) to strong (5/49: 10%) </plain></SENT>
<SENT sid="12" pm="."><plain>MM were found in 30% of CCR5 negative and in 23% of CCR5 positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients by the K-ras-specific PCR-RFLP assay </plain></SENT>
<SENT sid="13" pm="."><plain>The nested CK20/GCC RT-PCR assay detected MM in 87% of CCR5 negative and in 27% of CCR5 positive <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients (P = 0.00002) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Thus, CCR5 expression of the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> might be a valuable biomarker indicating the absence of hepatic molecular <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
</text></document>